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Abstract
Background: Breast carcinomas represent a heterogeneous group of tumors diverse in behavior, outcome, and
response to therapy. Identification of proteins resembling the tumor biology can improve the diagnosis,
prediction, treatment selection, and targeting of therapy. Since the beginning of the post-genomic era, the focus
of molecular biology gradually moved from genomes to proteins and proteomes and to their functionality.
Proteomics can potentially capture dynamic changes in protein expression integrating both genetic and epigenetic
influences.
Methods: We prepared primary cultures of epithelial cells from 23 breast cancer tissue samples and performed
comparative proteomic analysis. Seven patients developed distant metastases within three-year follow-up. These
samples were included into a metastase-positive group, the others formed a metastase-negative group. Two-
dimensional electrophoretical (2-DE) gels in pH range 4–7 were prepared. Spot densities in 2-DE protein maps
were subjected to statistical analyses (R/maanova package) and data-mining analysis (GUHA). For identification of
proteins in selected spots, liquid chromatography-tandem mass spectrometry (LC-MS/MS) was employed.
Results: Three protein spots were significantly altered between the metastatic and non-metastatic groups. The
correlations were proven at the 0.05 significance level. Nucleophosmin was increased in the group with
metastases. The levels of 2,3-trans-enoyl-CoA isomerase and glutathione peroxidase 1 were decreased.
Conclusion: We have performed an extensive proteomic study of mammary epithelial cells from breast cancer
patients. We have found differentially expressed proteins between the samples from metastase-positive and
metastase-negative patient groups.
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Background
Breast cancer is the most common cancer affecting women
worldwide. Human breast carcinomas represent a hetero-
geneous group of tumors diverse in behavior, outcome,
and response to therapy. Despite tremendous advances in
screening, diagnosis, and treatment, causes of this disease
remain elusive and complex.
It has been hypothesized that the clinical and genetic het-
erogeneity of breast cancer is a result of activation of dif-
ferent oncogenes or loss of different tumor suppressor
genes in specific stem/progenitor cells [1]. The genetic and
immunohistochemical analysis led to further clasification
of human breast cacinomas as basal or luminal according
to their cell type origin. To date, five types of breast carci-
nomas have been recognized according to the molecular
genetics profiling [2,3].
The nature of molecular changes varies between breast
tumors and determines the characteristics of the disease.
Current research priority is to develop methods to identify
the most informative molecular changes, also known as
disease markers. Thus the treatment strategy could be
optimized and individualized using molecular-biological
properties of the patient's tumor cells.
At present, several prognostic and predictive factors are
commonly used in the breast carcinoma treatment. They
include clinical factors such as tumor size, stage and his-
tological type, histological grade, number and scale of
regional lymph node involvement, hormone-receptor lev-
els (ER, PR), HER-2/neu expression level and nuclear
DNA ploidy. The significance of these factors has been
clearly determined and together with the clinical state of
the patient they are the main determinants in the process
of selection of treatment modality [4]. Despite the
research and treatment advances, the outcome of patients
is still often poor. Clearly, there is a critical need to find
new molecular parameters not only for detection, but also
for classification and treatment of the breast cancer.
Proteomics is a rapidly developing field that can explore
the heterogeneity of breast cancer and supplement the
wealth of information gained from genomics. Breast can-
cer is one of the most studied cancers in proteomics. Stud-
ies investigating differential expression of proteins
between normal and breast cancer cells revealed changes
in the composition of cytoskeletal elements such as cytok-
eratin distribution and tropomyosin expression, the dif-
ferential distribution of molecular chaperones (heat
shock protein family members, protein folding enzymes,
14-3-3 σ) has been described together with elevated levels
of glycolytic enzymes (aldolase, glyceraldehyde dehydro-
genase) [5,6]. Roles of lysozomal proteases (cathepsin D,
cathepsin B) and matrix metalloproteases (MMPs) in the
breast cancer development and progression have been
explored [7].
However, proteomic analysis of larger amounts of clinical
samples is so far a challenge [8]. Two-dimensional gel
electrophoresis (2-DE) facilitates the separation of pro-
teins from highly complex protein mixtures and has
become a central method in proteomics in recent years.
Unfortunately, the 2-DE methodology remains labor
intensive and also the subsequent gel analysis is difficult.
Although the 2-DE processing softwares are continuously
developing, their full automation is immense [9,10]. The
methodology also puts demands on sample amount and
composition. Selection of the most convenient samples
containing sufficient amount of proteins suitable for 2-DE
proteomic analyses is of crucial importance. Whereas dif-
ferential proteomic analysis of breast tissue biopsies is
complicated due to heterogeneity of cellular phenotypes
contained in the sample [11], cells in culture represent a
homogenous system, which can be to a certain extent
defined and specifically altered.
Optimized feeder layer technique was adapted for cultiva-
tion of mammary gland epithelial cells [12]. Successful in
vitro expansion of luminal cells together with myoepithe-
lial cells in heterogeneous populations of human breast
epithelial cells was achieved. It is assumed that among the
bulk of cells forming the body of the tumor only a few
drives the tumor outgrow. They are supposed to be
derived from the so-called stem or progenitor cells
[13,14]. Recently, we have characterized a new cell line,
EM-G3, possessing some characteristics of putative breast
progenitor cells. The cell line was established from the pri-
mary culture of breast cancer biopsy sample using the
optimized feeder layer technique [15,16]. We believe that
our method of temporal in vitro propagation of cells from
breast cancer tissues could partially lead to the selection of
cells relatively close to putative tumor stem cells [12,17].
We performed the 2-DE protein analysis of malignant
breast cancer cells cultivated from tissues of different
patients in various stages of breast cancer. We tried to find
association among possible variations in the expression of
proteins and clinical outcome of breast cancer patients. R/
computing environment was used to perform statistical
analyses [18]. Namely, the analyses based on the R/
maanova package [19] have been performed. We further
employed the data-mining technique GUHA (General
Unary Hypothesis Automaton) to reveal possible rela-
tions among protein spots and their impact on clinical
image [20]. The GUHA is a method of exploratory data
analysis with logical and statistical backgrounds. It auto-
matically formulates and tests a huge amount of hypoth-
eses on relations in data and reveals the "interesting"
ones. Some potential candidates for protein markers
ensue from these trials.BMC Cancer 2008, 8:107 http://www.biomedcentral.com/1471-2407/8/107
Page 3 of 13
(page number not for citation purposes)
Methods
Patients
The samples were obtained in the years 1999 – 2002 from
women who underwent partial breast resection or radical
mastectomy at the General Faculty Hospital in Prague.
Patients were chosen unselectively at the time of opera-
tion. The patient's written informed consent approved by
the Ethical committee of the General Faculty Hospital in
Prague was obtained prior to surgery. The morphology of
tumors was determined and immunocytochemical stain-
ing for hormonal receptors (ER, PR), HER 2/neu and anti-
gen Ki67 was performed. The patients were treated
according to the stage-adjusted therapeutic standards. We
estimated the clinical outcome of the patients. The
patients with follow-up at least three years were chosen
for further analysis. The patients were divided into two
groups: distant metastase-free after three years and
patients with proven distant metastases.
Immunohistochemistry
Paraffin sections 5 µm from formalin-fixed tissues were
used. The tissue sections were incubated with primary
antibodies ER, Dako (Glostrup, Denmark), clone 1D5,
dilution 1 : 100; PR, Novocastra (Newcastle, UK) clone
16, dilution 1 : 100; Ki67, Novocastra (Newcastle, UK)
clone MIB-1, dilution 1 : 50. Immunodetection was per-
formed with the universal immuno-peroxidase polymer
Histofine, Nichirei Biosciences INC (Tokyo, Japan).
Detection of HER 2/neu was performed using HercepTest
TM assay detection system, Dako (Glostrup, Denmark).
Five percent 3,3'-diaminobenzidine tetrahydrochloride
chromogen solution was used for visualization. Positive
and negative controls were included in each run of slides.
Cell cultures
Primary cell cultures were isolated from biopsies of
human breast carcinomas. The cells were cultured by the
3T3 feeder-layer technique [12,17].
The cells in the second or third passage were grown to con-
fluence, harvested and stored in liquid nitrogen in the cul-
ture medium containing 10% dimethylsulfoxid and 20%
of bovine serum. The cells designated for 2-DE analyses
were thawed, seeded, cultivated to confluent layers and
harvested as described in Selicharova et al. [15]. Out of
120 cultivated samples, primary cultures from tumor tis-
sue of 23 patients were suitable for further 2-DE based
analysis because of a sufficient amount of cultivated cells
(about five millions).
Two-dimensional gel electrophoresis
The cell lysate (70 µg of proteins) in rehydration buffer
composed of 7 M urea, 2 M thiourea, 4% (w/v) CHAPS,
50 mM DTT, 0.8% (v/v) ampholytes (pH 3–10) was
applied to 18 cm linear IPG strips pH 4–7, GE Healthcare
(Uppsala, Sweden). 2-DE was performed exactly as
described [15]. Briefly, the IEF of rehydrated strips was
performed with stepwise increasing voltage as follows:
250 V for 1 h, 500 V for 1 h, 1000 V for 2 h and 10,000 V
for the time period necessary to reach 70,000 Vh in total.
The focused strips were equilibrated for 30 min in the
solution containing 6 M urea, 20% (v/v) glycerol, 2% (w/
v) SDS, 0.05 M Tris/HCl pH 8.8 and 2% (v/v) DTT with
traces of Bromphenol Blue. Then free thiol groups were
alkylated for 30 min in the same solution containing
2.5% (w/v) iodoacetamide instead of DTT. The SDS-PAGE
on gradient gels (8–16%, 4% stacking gel, 19 × 22 cm)
was performed in 0.025 M Tris/0.192 M Glycine with
0.1% (w/v) SDS running buffer for 1 h at 16 mA and for
about 9 h at 24 mA per gel till the Bromphenol Blue line
has reached the bottom of the gel. Three silver-stained
analytical gels were prepared from each sample. All the
common chemicals were from Sigma (St. Louis, USA) and
Fluka (Buchs, Switzerland).
Image analysis
Gels were scanned by a GS-800 Calibrated Densitometer,
Bio-Rad (Hercules, CA) at 700 dpi resolution. The images
were further processed by PDQuest Advaced 8.0.1 2D Gel
Analysis Software, Bio-Rad (Hercules, CA). For computa-
tional purposes the file size was reduced to 50% and the
images were cropped to frame the same clusters of spots.
One or two representative gels per each cell population
were used to create a match-set. Spots were detected and
matched automatically to a master gel selected by the soft-
ware. The spot detection and matching were edited man-
ually. The spot boundary tool was applied to detect large
spots. The patterns in sections of the gels in appropriate
magnification were checked and spots were added manu-
ally to the master gel to allow matching unique spots
present in the individual gels. The spot quantity table con-
taining all matched spots was generated. The quantity of
missing spots was estimated by the software. The means of
logarithmic ratios method was used for normalization.
The mean of log ratios method of normalization calcu-
lates the normalization factor of a gel by calculating the
mean of all log ratios (log spot quantity of gel/log spot
quantity of master gel) of all matched spots (master gel –
gel). The quantity table was exported to a spreadsheet .xls
file and submitted to statistical analyses (Additional data
file 1).
Statistical analysis and data mining – GUHA (General 
Unary Hypothesis Automaton)
Independent statistical tests were performed using R/com-
puting environment in version 2.6.0 [18] and by adapting
R/maanova package version 1.8.0. [19] which has been
designed for processing microarray data. It implements
sample shuffling. R/maanova provides a permutation
method to calculate the nominal permutation p-values forBMC Cancer 2008, 8:107 http://www.biomedcentral.com/1471-2407/8/107
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each gene (i.e. spot intensity) using Fs test statistics.
Because of multiple testing, the p-values were adjusted to
false discovery rate [21].
The relations among spot intensities and clinical image
were analyzed on the basis of data-mining technique
GUHA [20]. The analyzed data were stored in a source
database in the form of a table of n rows (objects = 2-DE
gels) and m columns (variables = spot intensities). The
variables were dichotomized. Each variable was catego-
rized. Categories were actually subsets of ranges of varia-
bles given by cut points. The category was evaluated as 1
if the value of a variable dropped within a subset given by
the respective cut point otherwise it was evaluated as 0.
The settings of cut points were based on the specification
and behavior of an impurity function [22]. In our applica-
tion we employed the entropy function as impurity func-
tion for each intensity variable classified with respect to
the clinical variable metastases. The impurity function
takes its minimum if all objects are classified as 0 or 1. The
maximum is reached if roughly a 50/50 mixture of classes
is present in the group. The idea is to split the original
group into two sub-groups in such a way that impurity
decreases in a maximal way, i.e., that the sum of impuri-
ties of sub-groups is minimized. We identified optimal
splits and corresponding optimal cut points by a script in
MATLAB [23]. The cut points then enabled us to catego-
rize spot intensities. A GUHA hypothesis is determined by
the ordered pair of cedents (antecedent (A) and succedent
(S)) and by a quantifier. Cedents are Boolean conjunctions
formed from individual categories. The length of a cedent
is given by the number of categories forming the conjunc-
tion. A cedent of length = 1 corresponds to a single cate-
gory (simple cedent). Cedents of length > 1 are called
compound cedents. For a given object a cedent can be
evaluated as 1 (true) or 0 (false). The evaluation stems
from the evaluation of single categories forming the
cedent and rules for Boolean conjunction. For a given pair
of cedents, we can construct a corresponding contingency
table by evaluating cedents for all objects in the database
and then perform statistical tests on this table. The
employed quantifier determines the type of test. We used
the Fisher quantifier corresponding to Fisher's exact test. A
hypothesis is formally written A ~S, and if it is valid (sta-
tistically significant), it is revealed in the GUHA output.
Q-values were calculated by q-val package [21]. Statistical
tests were two-sided at the 5% level of significance.
Characterization of proteins
The spots generated from the statistical analyses as signif-
icantly changed were researched by their spot ID in the
match set created by the PDQuest software. The relative
molecular masses (Mr) and isoelectric points (pI) were
estimated for each protein from their positions in the gels.
The statistically important spots were considered for iden-
tification. The preparative 2-DE gels were prepared from
cells with a relatively high content of the protein of inter-
est using 400 µg of the cell lysate. They were stained with
colloidal Coomassie stain [24].
Mass spectrometry and protein identification
Selected spots on the preparative gels were excised and
destained using 50% acetonitrile in 25 mM ammonium
bicarbonate, dehydrated with 200 µl of acetonitrile for 5
min at 30°C using thermomixer comfort, Eppendorf AG
(Hamburg, Germany) at 30°C and then vacuum-dried in
SpeedVac, Thermo Scientific (Waltham, Ma). Gel pieces
were rehydrated and proteins were digested for 8 hours at
37°C in the thermomixer with 30 ng/µl trypsin (Trypsin
Gold Mass Spectrometry Grade, Promega, Madison, WI)
in 25 mM ammonium bicarbonate. After digestion, pep-
tides were extracted from gel pieces using step by step
extraction with acetonitrile gradient (15%–60% ace-
tonitrile with 1% trifluoroacetic acid). The extraction was
performed in sonicator, Elma (Singen, Germany) with ice
cubes.
Extracted peptides were concentrated in SpeedVac,
Thermo Scientific (Waltham, Ma). Tandem electrospray
ionization mass spectrometry (ESI-MS/MS) was used to
characterize the digests. The ESI-MS/MS was performed in
a quadrupole-time of flight (Q-TOF) tandem Micro mass
spectrometer (Waters-Micromass) equipped with nanoe-
lectrospray source and coupled to 2-D capillary chroma-
tography CapLC (Waters). Chromatographic separation
was achieved using the symmetry 300 Å OPTI-PAC (1 cm
× 5 µm) trap column (Waters) and Atlantis dC18 (75 µm
× 10 cm × 3 µm) capillary column (Waters). Data were
processed by proteomic software Proteinlynx global server
2.1 (Waters) (LC-MS/MS).
Results
Clinico-pathological characteristics of the patients
Primary cultures of breast epithelial cells available for 2-
DE analysis were cultivated from biopsy specimens of 23
breast cancer patients. An example of ER, PR and HER 2/
neu positive immunocytochemical staining of tumor tis-
sue of patient L116 together with in vitro outgrowths of
the cells are shown in Figure 1(A–E). The example of pos-
itive staining for Ki67 with MIB-1 in Figure 1(F) is shown
for sample L122. Dominating histology of tumors were
invasive ductal carcinomas (16 patients), mostly high
grade, five lobular carcinomas, one of them pleomorphic,
one mucinous and one medulary carcinoma. Sixteen
tumors were ER-positive, seven were ER-negative includ-
ing three carcinomas, which were triple-negative (ER-neg-
ative, PR-negative, HER 2/neu negative). Four tumors
were stained as HER 2/neu 3+ and five other were HER 2/
neu 2+. The main tumor characteristics are given in Table
1. Metastatic spreading was proven in seven patients dur-BMC Cancer 2008, 8:107 http://www.biomedcentral.com/1471-2407/8/107
Page 5 of 13
(page number not for citation purposes)
Examples of positive staining of tumoral tissue sections Figure 1
Examples of positive staining of tumoral tissue sections. A) Invasive ductal carcinoma, patient L116. Hematoxylin-eosin 
stain in 200× magnification reveals poor differentiation with a predominantly solid infiltrative pattern. The nuclei are highly ple-
omorphic with notable nucleoli. B) Outgrowths of cells from tumor fragment in vitro phase contrast (400× magnified). C) 
Immunostaining for ER, patient L116 (100× magnified). D) Immunostaining for PR, patient L116 (100× magnified). E) Immunos-
taining for HER 2/neu, patient L116 (400× magnified). F) Immunostaining for Ki67 with MIB-1 antibody, patient L122 (400× 
magnified).BMC Cancer 2008, 8:107 http://www.biomedcentral.com/1471-2407/8/107
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ing postoperative follow-up. The pattern of metastases
and time to relapse are given in Table 2.
We intended to find differences in protein expression
between the samples from metastase-positive and metas-
tase-negative patient groups.
2-DE protein separation and image analysis
2-DE protein maps in the pH range 4–7 were prepared in
triplicate. The 2-DE protein maps were very similar in all
the cases and contained all the major spots that were iden-
tified in the normal mammary epithelial (NME) cell sam-
ple as described in [15]. A typical 2-DE gel is shown in
Figure 2. The main protein spots are marked. The gels
were analyzed by PDQuest Advanced 8.0.1 2D Gel Analy-
sis Software. The software is not designed to compare
multiple groups of samples that arise from our experi-
mental setting (23 samples in triplicate). We compro-
mised between the quantity of data and our ability to
process them. The spot patterns in the area of the gels
above Mr 50 kDa were not homogeneous and were not
suitable for spot detection and matching by the PDQuest
software due to huge protein clusters formed by cytokerat-
ins and inconsistent streaks. Only spots in the pH range
from 4.2 to 6.8 and Mr range from 15 kDa to 40 kDa were
analyzed, matched and quantified. The area of the gel ana-
lyzed by PDQuest is outlined in Figure 2. A match-set con-
taining 44 gels was created. Twenty-one samples were
represented by two gels. Two samples were represented for
capacity and gel quality reasons by one gel only. The cor-
Table 1: Clinico-pathological characteristics of patients
Patient Age Stage Histology GRADE ER% PR% HER2 MIB-1%
L101 33 T2N2M0 invasive ductal 3 70 30 NEG 30
L103 48 T1N0M0 invasive ductal 2 85 100 3+ 10
L106 36 T1N0M0 invasive ductal 3 70 90 NEG 20
L116 54 T1N1M0 invasive ductal 3 90 90 3+ 10
L118 75 T4N1M0 invasive ductal 3 NEG NEG 3+ 20
L122 75 T2N0M0 invasive ductal 3 NEG NEG NEG 80
L128 44 T1N0M0 invasive ductal 3 90 20 NEG 20
L133 81 T4N0M0 invasive ductal 2 80 60 2+ 5–10
L154 70 T1N0M0 invasive ductal 3 80 70 NEG 30
L176 74 T2N1M0 invasive ductal 3 NEG NEG 2+ 35
L180 77 T4N1M0 invasive ductal 2 100 70–80 3+ 10–20
L181 63 T1N0M0 invasive ductal 1 75 NEG NEG 35
L190 49 T3N1M0 invasive ductal 2 65 5 2+ 20
L42 51 T4N1M0 invasive ductal 3 70 70 NEG <5
L53 69 T4N0M0 invasive ductal 3 NEG NEG NEG 30
L67 61 T4N0M0 invasive ductal 3 NEG NEG NEG 30
L143 68 T1N0M0 invasive lobular 20 30 1+ <5
L187 57 T2N1M0 invasive lobular 90 NEG NEG 10
L40 52 T4N2M0 invasive lobular NEG NEG 2+ 10
L43 51 T2N1M0 invasive lobular 30 70 NEG <5
L174 29 T1N0M0 medullary 3 NEG <5 NEG 70
L179 73 T1N0M0 mucinous 2 100 90 2+ 5
L50 52 T2N1M0 tubulolobular 30 NEG NEG 30
The age of patients, stage in the TNM classification, histology, grade of tumors and HER 2/neu (HER2), estrogen receptor (ER), progesterone 
receptor (PR), and nuclear protein Ki67 (MIB-1) percentage of immunostained cells are listed for each patient. The patients constituting the 
metastase positive group are in bold.
Table 2: Metastatic pattern of patients in the metastase positive group
Patient Age (years) Time to relapse (month) Metastases
Lung Bone Liver Soft tissue
L118 75 3.9 yes
L128 44 32.2 yes yes yes yes
L180 77 11.8 yes yes
L190 49 4.0 yes
L40 52 12.8 yes yes
L53 69 17.7 yes yes
L67 61 26.5 yesBMC Cancer 2008, 8:107 http://www.biomedcentral.com/1471-2407/8/107
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relation coefficients between technical replicates of gels
ranged from 0.76 to 0.88. Matching of the most typical
spots was checked and corrected manually. The spot pat-
terns in distinct areas of gels were studied and spots
unique to individual gels were added to the master gel to
allow their analysis. Finally, 245 spots were matched and
70 of them were matched to all gels. The log-normalized
spot quantity table containing all matched spots was gen-
erated and submitted to statistical analyses (Additional
file 1).
Statistical analysis and data mining
We searched for protein spots changed between the seven
samples of metastase-positive and sixteen samples of
metastase-negative groups.
For the GUHA analysis we averaged the intensity values
for each sample. Categorization of 245 spot variables was
determined on the basis of specification of maximal
impurity decrease generating cut points. The basic task
was to search for statistically significant relations between
the presence/absence of spots and their classifications
(metastatic/non-metastatic). In GUHA task settings, the
Representative 2-DE map Figure 2
Representative 2-DE map. Representative 2-DE map of proteins of primary culture of epithelial breast cancer cells (sample 
L116). The gels were silver-stained. Solubilized proteins were focused on IPG strips (pH 4–7) and separated in SDS polyacryla-
mide gradient gels (8–16%). The characteristic proteins are named according to [15], A = annexin, CK = cytokeratin, eIF = 
eukaryotic translation factor, FABP = fatty acid-binding protein, GST = glutathione transferase, HSP = heat-shock protein, PDI 
= protein disulfide isomerase, TCTP = translationally controled tumor protein, TPI = triosephosphate isomerase. Protein spots 
significantly changed between the metastase-positive and metastase-negative samples are marked and described in Tables 3, 4, 
5. The area of gel analyzed using PDQuest is outlined (------).BMC Cancer 2008, 8:107 http://www.biomedcentral.com/1471-2407/8/107
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antecedent variables were spot variables, succedent varia-
bles clinic variables. The lengths of antecedent and suc-
cedent were set to 1 and Fisher quantifier was employed.
We searched for hypotheses rejecting the null hypothesis
on independence between the presence/absence of spots
and classification of 2-DE gels. Tests were taken at the 0.05
probability level. However, because we performed many
simultaneous tests we had to adjust the significance level
using the q-value. The q-value was calculated from the
value of corresponding Fisher statistics. Q-values repre-
sent the approximation of maximal false-positive rate
among the proteins supposed to be significant. Spots
7305 and 1606 fulfilled the criteria of q-value ≤ 0.05. The
data from the GUHA analysis are presented in Table 3. We
are showing 10 spots with the lowest q-values. The com-
plete data can be found in Additional file 2.
The false discovery rate adjusted p-value and the fold
change were calculated using the R/maanova package
[19]. All spots are presented in volcano plot (Huy) with
log 2 fold change on x-axis and -log 10 (adjusted P-value)
as y-axis (Figure 3). Spots 7305 and 5104 fulfilled statisti-
cal criteria of adjusted p-value ≤ 0.05 and log2 fold change
≥ 2 estimated by maanova. The data from maanova anal-
ysis are presented in Table 4. We are showing 10 spots
with the lowest p-values and log2 fold change ≥ 1. The
complete data can be found in Additional file 3.
We considered the spots 7305, 5104 and 1606 that have
been found by either type of computing as significantly
changed in correlation with the metastases. The spots
5104 and 7305 were negatively correlated with the meta-
static phenotype, the spot 1606 was correlated positively.
Characterization of proteins
The spots found by the statistical analyses were re-
searched in the match-set created by the PDQuest soft-
ware. The spots are marked in Figure 2 and enlarged sec-
tions of representative gels showing the respective spots in
the metastatic and non-metastatic groups are presented in
Figure 4. The data from protein identification are pre-
sented in Table 5. The identity of all peptides has been
confirmed at least by three fragment ions in the MS/MS
spectrum.
Spot 1606 had a diffused pattern in the 2-DE gel. It was
identified as nucleophosmin, [Swiss-Prot:P06748]. Spots
7305 and 5104 were of very low intensity as could be esti-
mated from the cut-off values and judged from Figures 2
and 4. Spot 7305 was identified as 2,3-trans-enoyl-CoA
isomerase, [Swiss-Prot:P42126]. Spot 5104 was identified
as glutathione peroxidase 1, [Swiss-Prot:P07203].
Discussion
Breast cancer is one of the most intensively studied can-
cers. However, the breast cancer research proved to be
extremely complicated due to the complex biology of
mammary gland [11,14]. We believe that our method of
temporal in vitro propagation of cells from breast cancer
tissues [12,17] could partially lead to the selection of cells
relatively close to putative tumor stem/progenitor cells.
We suppose that through analysis of these cells we might
indicate proteins responsible for the overall tumor behav-
ior. We performed the 2-DE analysis of 23 primary cul-
tures of epithelial cells derived from breast cancer tissues
from which seven samples were metastase-positive.
All the 2-DE gels from different samples were similar to
each other and were conformable to the normal mam-
mary epithelial (NME) cell sample described in Selicha-
rova et al [15]. The similarity of individual primary
Table 3: GUHA data mining analysis
Spot Metastases Cut point Fisher q-value
7305 0 4.1 0.000069 0.0164
1606 1 67.6 0.000490 0.0370
5104 0 2.2 0.003953 0.0852
4503 0 0.8 0.003953 0.0852
4103 0 2.4 0.003953 0.0852
1502 0 2.9 0.023960 0.1637
1002 0 3.1 0.025731 0.1637
4302 0 5.4 0.045004 0.2342
1001 0 19.3 0.045004 0.2342
8105 0 3.4 0.083004 0.2342
For each spot we show the number given by PDQuest software, 
hypotheses tested in GUHA (metastases = 1, no metastases = 0), cut 
points estimated from log-normalized density with maximal impurity 
function decrease, the value of Fisher statistics corresponding to 
Fisher's exact test (fisher) and maximal false-positive rate 
approximation among the proteins supposed to be significant (q-
value).
Table 4: R/maanova
Spot Fold change (log2) Fs Pvalperm Fs adjPvalperm
5104 2.948184844 0.000152284 0.020651332
7305 2.401019096 0.000203046 0.020651332
1606 -1.190211206 0.000456853 0.030976998
1502 3.018100581 0.002538071 0.086047217
8105 1.613027626 0.003959391 0.100675244
4302 1.414239041 0.005482234 0.100873814
1002 2.772977926 0.006395939 0.100873814
5301 3.016324495 0.006446701 0.100873814
4503 2.329847113 0.008629442 0.116809097
4103 1.547766562 0,013248731 0.150633246
For each spot we show the number given by PDQuest software, log2 
difference of log-transformed means between metastases and non-
metastases groups (fold change), nominal permutation p-values using 
Fs test statistics (Fs Pvalperm) and false discovery rate-adjusted p-
values for multiple testing (Fs adjPvalperm).BMC Cancer 2008, 8:107 http://www.biomedcentral.com/1471-2407/8/107
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Volcano plot Figure 3
Volcano plot. The dots represent the individual spots from 2-DE analysis. The y-axis value is -log10(P-value) for the Fs test 
and the x-axis value is proportional to the fold changes (Huy, maanova [19]). The horizontal line represents the significance 
threshold 0.05 (Fs-adjusted). The red dots are the spots selected by the Fs test. Significantly changed spots are marked.
Table 5: Identification of significantly changed proteins between the metastase-positive and metastase-negative groups
Spot Swiss-Prot
protein name
Measured Mr/pI Theor. Mr/pI Sequence coverage (%) Peptides sequenced Score
7305 P42126 27/6.3 28/6 17 47–61 VLVEPDAGAGVAVMK 103
2,3-trans-Enoyl-CoA 191–200 DTLENTIGHR 48.6
Isomerase 271–283 DADVQNFVSFISK 18
289–296 SLQMYLER 20.4
5104 P07203 22/5.9 21/6.1 10 147–155 LITWSPVC*R 5.4
Glutathione peroxidase 1 165–175 FLVGPDGVPLR 12.1
1606 P06748 37/4.7 33/4.6 26 33–45 VDNDENEHQLSLR 53.6
Nucleophosmin 55–73 DELHIVEAEAMNYEGSPIK 37.5
81–101 MSVQPTVSLGGFEITPPVVLR 65.8
238–246 GPSSVEDIK 20
276–289 MTDQEAIQDLWQWR 24.9
For each spot we show the number given by PDQuest software, the accession number to the Swiss-Prot database, name, experimentally found 
(measured) and theoretical (theor.) relative molecular masses in kDa (Mr) and isoelectric points (pI), achieved sequence coverage (%), peptides 
sequenced by the LC-MS/MS, their composition, position and peptide score. C*: modified cystein detected as carbamidomethylBMC Cancer 2008, 8:107 http://www.biomedcentral.com/1471-2407/8/107
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cultures of breast cancer cells was a good prerequisite for
performing the comparative proteomic experiment. On
the other hand, the experimental design based on the pri-
mary cultures substantially decreased the available
amount of samples necessary for powerful statistics. From
120 human breast tumors we only obtained 23 usable cell
cultures with a sufficient amount of cultured cells (about
five millions).
Only few spots apparently varied among sets of gels from
individual samples qualitatively or quantitatively. Some
of the proteins have been identified (data not shown). We
detected variations in quantity of cathepsin D, cathepsin
B, squamous cell carcinoma antigen, γ synuclein, cytoker-
atin 19 and other proteins that have been reported to play
a role in cancer etiology [25-29]. We also found isoelectric
variants of several proteins arising from common poly-
morphism that might have impact on the cancerogenesis
(glutathione transferase ω, glyoxalase I) [30,31]. On the
other hand we have not observed variation in quantity of
heat shock proteins (HSP 90, HSP 60, HSP 27) or the
molecular chaperone 14-3-3 σ among our breast cancer
cell cultures. These proteins have been reported to be
altered in the breast cancer [5,32]. Although these find-
ings were exciting, we could not demonstrate without fur-
ther validation the significance of above mentioned
observations and their connectedness with the tumor
characteristics.
We intended to perform computational quantitative anal-
ysis of our 2-DE data. Any computer software designed to
align and compare 2-DE gels must somehow deal with
Enlarged sections of representative 2-DE gels Figure 4
Enlarged sections of representative 2-DE gels. Enlarged sections of representative 2-DE gels showing differential expres-
sion of spots 7305, 5104 and 1606 between the metastic and non-metastic groups. The averaged relative intensities of particu-
lar spots in individual samples from the PDQuest output are shown in the bar graphs. The bars corresponding to the 
representative samples are marked. Sample order in the bar graph is the same as in Table 1 and in Table 2, the patient groups 
being separated.BMC Cancer 2008, 8:107 http://www.biomedcentral.com/1471-2407/8/107
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distorted spot patterns that are pertinent to the methodol-
ogy. So far, the spot detection and matching must be
supervised by a researcher [10] which was another bottle-
neck of our experimental design. We have analyzed our
gels by the PDQuest Advanced 8.0.1 2D Gel Analysis Soft-
ware since it is available in our laboratory. The software is
not designed to compare multiple groups of samples that
have arisen from our experimental setting (23 samples in
triplicate). We compromised between the quantity of data
and our ability to process them. We have finally con-
structed a match set composed of 44 cropped gels yielding
well distinguished spot patterns. The spot patterns were
carefully studied and matching was adjusted in each gel.
Finally, 245 spots were matched and their normalized
quantities in each gel were subjected to statistical analyses
and data mining. The quantification of proteins in 2-DE
gels is relative and it is a matter of dynamic range versus
sensitivity [8,24]. The gels were silver-stained because we
intended to achieve the utmost sensitivity to be able to
detect possible changes in the expression of less abundant
proteins in our samples. We are aware that this type of
staining might be a source of inaccuracy. The correlation
coefficients between technical replicates of gels ranged
from 0.76 to 0.88 which is normal for the 2-DE analyses
[9]. However, the overall variability within the data cut
down the attainable statistical significance of our results.
In spite of all the disputable issues we indicated spots cor-
related with metastases in the set of patients. We used two
different statistical approaches to search for significant
correlations between clinical data and spot intensities.
The GUHA [20] enriched with cut-off points and q-values
computes with categorical variables sorted according to
the cut points. The R/maanova [19] computes with inte-
gers that correspond to the spot densities. The outputs of
the methods slightly differ but in general the same spots
were found with both the methods as significantly corre-
lated with the clinical data.
Spots 7305, 5104 and 1606 fulfilled the statistical criteria
in either analysis. Spot 7305 was identified as 2,3-trans-
enoyl-CoA isomerase. The enzyme is involved in mito-
chondrial β-oxidation of unsaturated fatty acids [33]. The
defects in distribution of polyunsaturated fatty acids in
healthy and cancerous breast tissues have been docu-
mented [34]. Decreased levels of this enzyme might have
impact on the aberrant behavior of cancer cells.
Spot 5104 was identified as glutathione peroxidase 1, a
selenium dependent enzyme that detoxifies hydrogen and
lipid peroxides. The protective function of selenium
against cancer mortality has been documented. It remains
unclear how selenium decreases cancer risk and whether
glutathione peroxidase is involved in the action [35]. The
lowered levels of the enzyme in our group of patients with
metastases further support possible involvement of the
glutathione peroxidase 1 in the anticancer defense.
Spot 1606 was increased in the group of patients with
metastases and it appeared to be abundant. The spot had
a diffused pattern in the 2-DE gel and the MS spectra were
complicated. It was identified as nucleophosmin, a highly
phosphorylated protein associated with nucleolar ribonu-
cleoprotein structures [36]. The protein is known to be
extensively post-translationally modified. It might be a
reason for its 2-DE pattern but we cannot exclude that
there might be other proteins contained in the spot.
Nucleophosmin is overexpressed in many types of human
solid tumors. It is a multifunctional protein and its phys-
iological function in tumorigenesis is controversial [37].
Conclusion
We have performed an extensive proteomic study of
mammary epithelial cells from the breast cancer patients.
We found three proteins that were significantly altered in
the group of patients who developed distant metastases
within the three-year post-operative follow-up. After
development of preferably an immunocytochemical
detection methodology, our results need to be proven on
a higher amount of samples (directly on tumor biopsies)
to establish their value for prediction of tumor behavior,
spreading or as potential treatment targets. It should be
kept in mind that we were able to process only a small part
of the 2-DE maps. Potentially, more proteins may be
found if we analyze other portions of the proteomes of
our samples. The work is in progress.
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